You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
国家卫健委:新冠疫苗属公共产品 将全民免费提供
阿思达克 12-31 14:29
国务院联防联控机制科研攻关组疫苗研发工作组组长郑忠伟出席记者会时指,疫苗是公共产品的属性,只能以成本作为定价的依据,产品的成本,它的影响因素也是蛮多的,和它的生产规模、使用规模密切相关。他指出接种计划第一步将针对高风险人群、重点人群,第二步高危人群,第三步全人群的接种。随着工作的推开,料成本会得到大幅度下降,坚信新冠病毒疫苗的价格一定是在老百姓可接受的范围内。

另外国家卫健委副主任曾益新亦补充,疫苗的基本属性还是属於公共产品,价格可能会根据使用规模的大小有所变化,但大前提肯定是为全民免费提供。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account